You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Commentary on Aschmann et al: How do we incorporate harms in analyses of randomized trials?

Clinical Trials

Impact Factor: 2.2 / 5-Year Impact Factor: 2.3

Journal Homepage Submission guidelines

Restricted access

Letter

First published online April, 2022

Commentary on Aschmann et al: How do we incorporate harms in analyses of randomized trials?

Volume 19, Issue 2

https://doi.org/10.1177/17407745211068547

Abstract

Get full access to this article

View all access options for this article.

References

1.

Aschmann

HE

McNeil

JJ

Puhan

MA

. Large scale prevention trials could provide stronger evidence for decision makers: opportunities to design and report with a focus on the benefit-harm balance. Clin Trials, IN PRESS.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Clinician-trialist rounds: 25. Designing an evidence-based introductory graduate course in clinical trials. Part 2: Applying the evidence to your RCT course design

Retricted access

Applying justice in clinical trials for diverse populations

Retricted access

Reducing selection bias in a cluster randomized trial in West African villages

Retricted access

Book Review: Design of studies for medical research